{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T23:51:34Z","timestamp":1768780294355,"version":"3.49.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Treatment with adrenocorticotropic hormone (ACTH) or a corticosteroid is the first choice for infantile spasms (IS), and vigabatrin is the first choice for children with tuberous sclerosis. Although corticosteroids may be also effective against IS and IS-related Lennox\u2013Gastaut syndrome (LGS), the use of dexamethasone (DEX), a kind of corticosteroid, for these diseases has been rarely reported. This retrospective study aimed to evaluate the efficacy and tolerability of DEX for the treatment of IS and IS-related LGS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients diagnosed as having IS (including patients whose condition evolved to LGS after the failure of early treatment) in our hospital between May 2009 and June 2019 were treated with dexamethasone after failure of prednisone treatment. The oral dose of DEX was 0.15\u20130.3\u00a0mg\/kg\/d. Thereafter, the clinical efficacy, electroencephalogram (EEG) findings, and adverse effects were observed every 4\u201312 weeks depending on the individual patient\u2019s response. Then, the efficacy and safety of DEX in the treatment of IS and IS-related LGS were retrospectively evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 51 patients (35 cases of IS; 16 cases of IS-related LGS), 35 cases (68.63%) were identified as responders to DEX treatment, comprising 20 cases (39.22%) and 15 cases (29.41%) with complete control and obvious control, respectively. To discuss the syndromes individually, complete control and obvious control were achieved in 14\/35 and 9\/35 IS cases and in 6\/16 and 6\/16 IS-related LGS cases, respectively. During DEX withdrawal, 11 of the 20 patients with complete control relapsed (9\/14 IS; 2\/6 LGS). The duration of dexamethasone treatment (including weaning) in most of the 35 responders was less than 1 year. However, 5 patients were treated with prolonged, low-dose maintenance therapy, which continued for more than 1.5 years. These 5 patients showed complete control, and 3 patients had no recurrence. Except for one child who died of recurrent asthma and epileptic status 3 months after stopping DEX, there were no serious or life-threatening adverse effects during DEX treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Oral DEX is effective and tolerable for IS and IS-related LGS. all LGS patients were evolved from IS in this study. The conclusion may not apply to patients with other etiology and courses of LGS. Even when prednisone or ACTH is failed, DEX may still be considered as a treatment option. For children who respond to DEX but do not show complete control after 6 months of treatment, prolonged treatment with low-dose DEX administered in the morning might be considered.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12887-023-04062-6","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T03:51:55Z","timestamp":1684813915000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy analysis of oral dexamethasone in the treatment of infantile spasms and infantile spasms related Lennox\u2013Gastaut syndrome"],"prefix":"10.1186","volume":"23","author":[{"given":"Jieling","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangcheng","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuquan","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,23]]},"reference":[{"key":"4062_CR1","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.seizure.2010.01.008","volume":"19","author":"L Lagae","year":"2010","unstructured":"Lagae L, Verhelst H, Ceulemans B, et al. Treatment and long term outcome in West syndrome: the clinical reality. A multicentre follow up study. Seizure. 2010;19:159\u201364.","journal-title":"Seizure"},{"key":"4062_CR2","first-page":"31","volume":"22","author":"MA Malik","year":"2012","unstructured":"Malik MA, Tarrar MA, Qureshi AO, Zia-Ur-Rehman M. Clinical spectrum of infantile spasm at presentation. J Coll Physicians Surg Pak. 2012;22:31\u20134.","journal-title":"J Coll Physicians Surg Pak"},{"key":"4062_CR3","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/j.1528-1167.2010.02522.x","volume":"51","author":"AT Berg","year":"2010","unstructured":"Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on classification and terminology, 2005\u20132009. EPILEPSIA. 2010;51:676\u201385.","journal-title":"EPILEPSIA"},{"key":"4062_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S1474-4422(08)70292-8","volume":"8","author":"A Arzimanoglou","year":"2009","unstructured":"Arzimanoglou A, French J, Blume WT, et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol. 2009;8:82\u201393.","journal-title":"Lancet Neurol"},{"key":"4062_CR5","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.braindev.2013.10.008","volume":"36","author":"P Pavone","year":"2014","unstructured":"Pavone P, Striano P, Falsaperla R, Pavone L, Ruggieri M. Infantile spasms syndrome, West syndrome and related phenotypes: what we know in 2013. Brain Dev. 2014;36:739\u201351.","journal-title":"Brain Dev"},{"key":"4062_CR6","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1111\/j.1528-1167.2010.02657.x","volume":"51","author":"JM Pellock","year":"2010","unstructured":"Pellock JM, Hrachovy R, Shinnar S, et al. Infantile spasms: a U.S. consensus report. EPILEPSIA. 2010;51:2175\u201389.","journal-title":"EPILEPSIA"},{"key":"4062_CR7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.pediatrneurol.2011.08.010","volume":"45","author":"AR Paciorkowski","year":"2011","unstructured":"Paciorkowski AR, Thio LL, Dobyns WB. Genetic and biologic classification of infantile spasms. Pediatr Neurol. 2011;45:355\u201367.","journal-title":"Pediatr Neurol"},{"key":"4062_CR8","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1111\/epi.13057","volume":"56","author":"JM Wilmshurst","year":"2015","unstructured":"Wilmshurst JM, Gaillard WD, Vinayan KP, et al. Summary of recommendations for the management of infantile seizures: Task Force Report for the ILAE Commission of Pediatrics. EPILEPSIA. 2015;56:1185\u201397.","journal-title":"EPILEPSIA"},{"key":"4062_CR9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1055\/s-0036-1572411","volume":"47","author":"D Tibussek","year":"2016","unstructured":"Tibussek D, Klepper J, Korinthenberg R, et al. Treatment of infantile spasms: report of the Interdisciplinary Guideline Committee coordinated by the german-speaking Society for Neuropediatrics. NEUROPEDIATRICS. 2016;47:139\u201350.","journal-title":"NEUROPEDIATRICS"},{"key":"4062_CR10","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/ana.24594","volume":"79","author":"KG Knupp","year":"2016","unstructured":"Knupp KG, Coryell J, Nickels KC, et al. Response to treatment in a prospective national infantile spasms cohort. Ann Neurol. 2016;79:475\u201384.","journal-title":"Ann Neurol"},{"key":"4062_CR11","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1212\/WNL.0b013e318259e2cf","volume":"78","author":"CY Go","year":"2012","unstructured":"Go CY, Mackay MT, Weiss SK, et al. Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the child Neurology Society. NEUROLOGY. 2012;78:1974\u201380.","journal-title":"NEUROLOGY"},{"key":"4062_CR12","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0022-3476(83)80606-4","volume":"103","author":"RA Hrachovy","year":"1983","unstructured":"Hrachovy RA, Frost JJ, Kellaway P, Zion TE. Double-blind study of ACTH vs prednisone therapy in infantile spasms. J Pediatr. 1983;103:641\u20135.","journal-title":"J Pediatr"},{"key":"4062_CR13","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0022-3476(05)81379-4","volume":"124","author":"RA Hrachovy","year":"1994","unstructured":"Hrachovy RA, Frost JJ, Glaze DG. High-dose, long-duration versus low-dose, short-duration corticotropin therapy for infantile spasms. J Pediatr. 1994;124:803\u20136.","journal-title":"J Pediatr"},{"key":"4062_CR14","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1542\/peds.97.3.375","volume":"97","author":"TZ Baram","year":"1996","unstructured":"Baram TZ, Mitchell WG, Tournay A, Snead OC, Hanson RA, Horton EJ. High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study. Pediatrics. 1996;97:375\u20139.","journal-title":"Pediatrics"},{"key":"4062_CR15","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1111\/j.1528-1157.1997.tb00063.x","volume":"38","author":"F Vigevano","year":"1997","unstructured":"Vigevano F, Cilio MR. Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study. EPILEPSIA. 1997;38:1270\u20134.","journal-title":"EPILEPSIA"},{"key":"4062_CR16","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0140-6736(04)17400-X","volume":"364","author":"AL Lux","year":"2004","unstructured":"Lux AL, Edwards SW, Hancock E, et al. The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. Lancet. 2004;364:1773\u20138.","journal-title":"Lancet"},{"issue":"Suppl Pt 2","key":"4062_CR17","first-page":"172","volume":"56","author":"J Roger","year":"1989","unstructured":"Roger J, Dravet C, Bureau M. The Lennox-Gastaut syndrome. Cleve Clin J Med. 1989;56(Suppl Pt 2):172\u2013S180.","journal-title":"Cleve Clin J Med"},{"key":"4062_CR18","doi-asserted-by":"publisher","DOI":"10.1891\/9781617052439","volume-title":"Pellock\u2019s Pediatric Epilepsy: diagnosis and therapy","author":"JM Pellock Jr","year":"2017","unstructured":"Pellock JM Jr, Nordli DR, Sankar R, Wheless JW. Pellock\u2019s Pediatric Epilepsy: diagnosis and therapy. Fourth ed. New York: NY: Demos Medical Publishing; 2017.","edition":"Fourth"},{"key":"4062_CR19","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1212\/WNL.33.8.966","volume":"33","author":"OR Snead","year":"1983","unstructured":"Snead OR, Benton JW, Myers GJ. ACTH and prednisone in childhood seizure disorders. NEUROLOGY. 1983;33:966\u201370.","journal-title":"NEUROLOGY"},{"key":"4062_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.pediatrneurol.2009.07.011","volume":"42","author":"E Haberlandt","year":"2010","unstructured":"Haberlandt E, Weger C, Sigl SB, et al. Adrenocorticotropic hormone versus pulsatile dexamethasone in the treatment of infantile epilepsy syndromes. Pediatr Neurol. 2010;42:21\u20137.","journal-title":"Pediatr Neurol"},{"key":"4062_CR21","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.braindev.2006.12.002","volume":"29","author":"H Yamamoto","year":"2007","unstructured":"Yamamoto H, Fukuda M, Miyamoto Y, Murakami H, Kamiyama N. A new trial liposteroid (dexamethasone palmitate) therapy for intractable epileptic seizures in infancy. Brain Dev. 2007;29:421\u20134.","journal-title":"Brain Dev"},{"key":"4062_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yebeh.2015.10.003","volume":"55","author":"J Chen","year":"2016","unstructured":"Chen J, Cai F, Jiang L, Hu Y, Feng C. A prospective study of dexamethasone therapy in refractory epileptic encephalopathy with continuous spike-and-wave during sleep. Epilepsy Behav. 2016;55:1\u20135.","journal-title":"Epilepsy Behav"},{"key":"4062_CR23","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1177\/0883073814533148","volume":"30","author":"K Jones","year":"2015","unstructured":"Jones K, Snead OR, Boyd J, Go C. Adrenocorticotropic hormone versus prednisolone in the treatment of infantile spasms post vigabatrin failure. J Child Neurol. 2015;30:595\u2013600.","journal-title":"J Child Neurol"},{"key":"4062_CR24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.pediatrneurol.2015.05.004","volume":"53","author":"J Wanigasinghe","year":"2015","unstructured":"Wanigasinghe J, Arambepola C, Sri RS, Sumanasena S, Attanapola G, Randomized. Single-Blind, parallel clinical trial on efficacy of oral Prednisolone Versus Intramuscular Corticotropin on Immediate and continued Spasm Control in West Syndrome. Pediatr Neurol. 2015;53:193\u20139.","journal-title":"Pediatr Neurol"},{"key":"4062_CR25","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.spen.2016.05.001","volume":"23","author":"GL Holmes","year":"2016","unstructured":"Holmes GL. Effect of seizures on the developing brain and cognition. Semin Pediatr Neurol. 2016;23:120\u20136.","journal-title":"Semin Pediatr Neurol"},{"issue":"Suppl 1","key":"4062_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/088307380502000101","volume":"20","author":"JW Wheless","year":"2005","unstructured":"Wheless JW, Clarke DF, Carpenter D. Treatment of pediatric epilepsy: expert opinion, 2005. J Child Neurol. 2005;20(Suppl 1):1\u2013S.","journal-title":"J Child Neurol"},{"key":"4062_CR27","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1684\/epd.2007.0144","volume":"9","author":"JW Wheless","year":"2007","unstructured":"Wheless JW, Clarke DF, Arzimanoglou A, Carpenter D. Treatment of pediatric epilepsy: european expert opinion, 2007. Epileptic Disord. 2007;9:353\u2013412.","journal-title":"Epileptic Disord"},{"key":"4062_CR28","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.1440-1819.1995.tb02168.x","volume":"49","author":"S Ohtahara","year":"1995","unstructured":"Ohtahara S, Ohtsuka Y, Kobayashi K. Lennox-Gastaut syndrome: a new vista. Psychiatry Clin Neurosci. 1995;49:179\u2013S183.","journal-title":"Psychiatry Clin Neurosci"},{"key":"4062_CR29","first-page":"401","volume":"143","author":"J Roger","year":"1987","unstructured":"Roger J, Remy C, Bureau M, et al. [Lennox-Gastaut syndrome in the adult]. Rev Neurol (Paris). 1987;143:401\u20135.","journal-title":"Rev Neurol (Paris)"},{"key":"4062_CR30","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1111\/j.1528-1167.2011.03127.x","volume":"52","author":"FJ O\u2019Callaghan","year":"2011","unstructured":"O\u2019Callaghan FJ, Lux AL, Darke K, et al. The effect of lead time to treatment and of age of onset on developmental outcome at 4 years in infantile spasms: evidence from the United Kingdom Infantile Spasms Study. EPILEPSIA. 2011;52:1359\u201364.","journal-title":"EPILEPSIA"},{"key":"4062_CR31","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1111\/j.1528-1167.2006.00888.x","volume":"47","author":"ZR Primec","year":"2006","unstructured":"Primec ZR, Stare J, Neubauer D. The risk of lower mental outcome in infantile spasms increases after three weeks of hypsarrhythmia duration. EPILEPSIA. 2006;47:2202\u20135.","journal-title":"EPILEPSIA"},{"key":"4062_CR32","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1055\/s-2008-1059590","volume":"13","author":"R Riikonen","year":"1982","unstructured":"Riikonen R. A long-term follow-up study of 214 children with the syndrome of infantile spasms. NEUROPEDIATRICS. 1982;13:14\u201323.","journal-title":"NEUROPEDIATRICS"},{"key":"4062_CR33","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.yebeh.2009.01.023","volume":"14","author":"EH Kossoff","year":"2009","unstructured":"Kossoff EH, Hartman AL, Rubenstein JE, Vining EP. High-dose oral prednisolone for infantile spasms: an effective and less expensive alternative to ACTH. Epilepsy Behav. 2009;14:674\u20136.","journal-title":"Epilepsy Behav"},{"key":"4062_CR34","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1046\/j.1365-2265.2002.01580.x","volume":"57","author":"SF Ahmed","year":"2002","unstructured":"Ahmed SF, Tucker P, Mushtaq T, Wallace AM, Williams DM, Hughes IA. Short-term effects on linear growth and bone turnover in children randomized to receive prednisolone or dexamethasone. Clin Endocrinol (Oxf). 2002;57:185\u201391.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"4062_CR35","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/j.1528-1167.2006.00384.x","volume":"47","author":"T Araki","year":"2006","unstructured":"Araki T, Otsubo H, Makino Y, et al. Efficacy of dexamathasone on cerebral swelling and seizures during subdural grid EEG recording in children. EPILEPSIA. 2006;47:176\u201380.","journal-title":"EPILEPSIA"},{"key":"4062_CR36","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.seizure.2005.07.002","volume":"14","author":"H Verhelst","year":"2005","unstructured":"Verhelst H, Boon P, Buyse G, et al. Steroids in intractable childhood epilepsy: clinical experience and review of the literature. Seizure. 2005;14:412\u201321.","journal-title":"Seizure"},{"key":"4062_CR37","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1136\/adc.2004.051375","volume":"90","author":"R Gupta","year":"2005","unstructured":"Gupta R, Appleton R. Corticosteroids in the management of the paediatric epilepsies. Arch Dis Child. 2005;90:379\u201384.","journal-title":"Arch Dis Child"},{"key":"4062_CR38","doi-asserted-by":"publisher","first-page":"e18200","DOI":"10.1371\/journal.pone.0018200","volume":"6","author":"N Marchi","year":"2011","unstructured":"Marchi N, Granata T, Freri E, et al. Efficacy of anti-inflammatory therapy in a model of acute seizures and in a population of pediatric drug resistant epileptics. PLoS ONE. 2011;6:e18200.","journal-title":"PLoS ONE"},{"key":"4062_CR39","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1055\/s-2008-1065358","volume":"38","author":"ZL Liu","year":"2007","unstructured":"Liu ZL, He B, Fang F, Tang CY, Zou LP. Analysis of single nucleotide polymorphisms in the melanocortin-4 receptor promoter in infantile spasms. NEUROPEDIATRICS. 2007;38:304\u20139.","journal-title":"NEUROPEDIATRICS"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-023-04062-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-023-04062-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-023-04062-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T22:22:25Z","timestamp":1729462945000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-023-04062-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,23]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4062"],"URL":"https:\/\/doi.org\/10.1186\/s12887-023-04062-6","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,23]]},"assertion":[{"value":"6 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board at the Children\u2019s Hospital of Chongqing Medical University. Written informed consent was obtained from the parents of participants in the study. All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"255"}}